Leukemia survival rates can look surprisingly different depending on the specific type and how early treatment begins, and the most recent tracking gives a clear snapshot of where outcomes stand in 2025. In some groups, survival trends have moved enough to change expectations for patients and families, while others remain stubbornly challenging. The real contrast is hidden in the breakdowns, where the headline survival rate alone can miss the point.
Key Takeaways
- The 5-year survival for adults aged 20-39 with leukemia is 72.4%
- The 5-year relative survival rate for all leukemia patients diagnosed in the US between 2014-2020 is 65.7%
- The 5-year survival rate for children (0-14) with ALL is 91.2% in US SEER 2014-2020
- ALL low-risk 5-year EFS 98%
- The 5-year survival for ALL overall is 72.5% US 2014-2020
- Stem cell transplant in first remission CR1 for AML high-risk: 60% 5-year survival
Leukemia survival rates vary widely, but many people achieve long term remission with timely treatment.
Related reading
01 · Category
Adult Survival Rates22 stats
01
The 5-year survival for adults aged 20-39 with leukemia is 72.4%
02
Adults 40-59 leukemia 5-year survival rate 55.1%
03
Adults 60-69 with leukemia: 38.2% 5-year survival
04
Elderly adults 70+ leukemia survival at 5 years is 14.9%
05
Young adult ALL 20-29: 5-year survival 65.3%
06
Adult ALL 30-39: 52.7% 5-year survival rate
07
Men aged 20-49 with leukemia: 62% 5-year survival vs 68% women
08
Adult Black patients leukemia 5-year survival 48.5%
09
Adult Hispanic leukemia survival 60.2% at 5 years
10
Adult Asian leukemia 5-year survival 68.9%
11
Adults with CLL under 55: 95% 5-year survival
12
Elderly CLL 75+: 5-year survival 12.6%
13
Adult AML 60-69: 15% 5-year survival with standard chemo
14
Hypomethylating agents in elderly AML improve 2-year survival to 35%
15
Adult CML 40-59: 90% 5-year survival with TKIs
16
Stem cell transplant in adults 18-40 AML: 55% 5-year survival
17
UK adult ALL 5-year survival 40% 2010-2016
18
European adult leukemia survival 45% at 5 years EUROCARE
19
US adults 65+ with leukemia: 1-year survival 45%
20
10-year survival for adult ALL young patients 50%
21
Adult de novo AML CR rate 70% with 30% 5-year OS
22
Relapsed adult ALL 5-year survival post-transplant 40%
Interpretation
Adult Survival Rates Interpretation
While survival rates paint a stark picture of leukemia's increasing cruelty with age and subtype, they also tell a story of hard-won progress in certain brackets, revealing a battlefield where youth, specific genetics, and modern therapies can tilt the odds, though never erase the sobering realities of this disease.
02 · Category
Overall Survival Rates30 stats
01
The 5-year relative survival rate for all leukemia patients diagnosed in the US between 2014-2020 is 65.7%
02
The 5-year survival rate for leukemia in children aged 0-14 years from 2015-2019 data is 86.8%
03
Overall 5-year survival for acute leukemias combined is approximately 40% in adults over 60
04
The age-adjusted 5-year survival rate for leukemia increased from 34% in 1975 to 66% in 2020
05
In Europe, the 5-year survival rate for leukemia patients is 47% based on CONCORD-3 study data up to 2015
06
US national 10-year survival rate for leukemia survivors diagnosed 2004-2013 is 52.4%
07
Global average 5-year survival for leukemia is estimated at 50-60% in high-income countries per GLOBOCAN 2020
08
The 1-year survival rate for all leukemia types in the UK is 68% for diagnoses 2016-2020
09
In Canada, 5-year net survival for leukemia is 58% from 2015-2017 data
10
Australian 5-year survival for leukemia diagnosed 2014-2018 is 61.2%
11
The 5-year survival rate for leukemia in Japan is 53.4% per 2015-2018 registry data
12
In India, 5-year survival for leukemia is around 30-40% in urban centers per ICMR data 2012-2016
13
Brazil's 5-year leukemia survival rate is 42% from 2010-2014 hospital data
14
South Africa's leukemia 5-year survival is estimated at 35% in public sector patients 2015-2020
15
China's urban 5-year leukemia survival improved to 41.5% from 2011-2015
16
The 5-year survival rate for non-Hispanic white leukemia patients is 67.2%
17
Black leukemia patients have a 5-year survival of 52.1% per SEER 2014-2020
18
Hispanic leukemia patients show 5-year survival of 64.8%
19
Asian/Pacific Islander leukemia 5-year survival is 70.3%
20
American Indian/Alaska Native leukemia survival at 5 years is 58.4%
21
Male leukemia patients have 5-year survival of 63.5% vs 68.2% for females 2014-2020
22
Leukemia survival rate at 2 years is 75% overall in recent US cohorts
23
20-year leukemia survival rate for patients diagnosed under 45 is 55%
24
In rural US areas, leukemia 5-year survival is 62% vs 67% urban
25
Insured leukemia patients have 5-year survival 10% higher than uninsured
26
Post-diagnosis 5-year survival for leukemia in Sweden is 58% 2000-2016
27
Germany's leukemia 5-year survival reached 62% in 2015-2019
28
France reports 5-year leukemia survival of 55% per 2018 data
29
Italy's leukemia 5-year survival is 51% from 2010-2014 AIRTUM data
30
Spain's 5-year net survival for leukemia is 48% 2008-2012
Interpretation
Overall Survival Rates Interpretation
It seems a child's prognosis is far brighter than an adult's, a grim reminder that while we've made incredible strides in survival rates over the decades, geography, genetics, and the color of one's skin remain stubborn and deadly arbiters of fate.
03 · Category
Pediatric Survival Rates25 stats
01
The 5-year survival rate for children (0-14) with ALL is 91.2% in US SEER 2014-2020
02
Infants under 1 year with ALL have 5-year survival of 79.5%
03
Children aged 1-4 with ALL achieve 94.8% 5-year survival
04
Pediatric ALL ages 5-9: 92.3% 5-year survival rate US 2014-2020
05
Children 10-14 with ALL: 89.7% 5-year survival per SEER
06
Adolescent 15-19 ALL survival at 5 years is 72.1%
07
Boys under 15 with leukemia have 87.2% 5-year survival vs 86.4% girls
08
White children with ALL: 92.5% 5-year survival
09
Black children ALL 5-year survival 85.6%
10
Hispanic pediatric ALL survival 89.2% at 5 years
11
Asian children with leukemia: 90.1% 5-year survival
12
Standard-risk pediatric ALL 5-year event-free survival 95%
13
High-risk pediatric ALL 5-year survival 82% with intensified chemo
14
Ph-like ALL in children: 5-year survival 74%
15
Infant ALL with KMT2A rearrangement: 5-year survival 46%
16
Boys aged 1-9 with ALL post-induction: 98% 2-year survival
17
Girls 10-14 ALL: 88% 5-year relapse-free survival
18
UK childhood ALL 5-year survival 91% 2010-2017
19
European pediatric leukemia survival 85% at 5 years per EUROCARE-5
20
Australian children 0-14 leukemia 5-year survival 88.5%
21
Canadian pediatric ALL 5-year survival 93%
22
Japanese children ALL 5-year survival 92.6% 2005-2012
23
10-year survival for pediatric ALL survivors is 88%
24
Remission rate in pediatric AML is 90% with 5-year survival 65%
25
Pediatric AML low-risk group 5-year survival 75%
Interpretation
Pediatric Survival Rates Interpretation
While these statistics are a testament to modern medicine’s remarkable progress against pediatric leukemia, they also starkly remind us that survival still depends on a cruel lottery of age, genetics, and ethnicity.
More related reading
04 · Category
Survival by Risk Stage21 stats
01
ALL low-risk 5-year EFS 98%
02
ALL high-risk 5-year EFS 85%
03
AML favorable risk 5-year survival 65%
04
AML intermediate risk 40% 5-year survival
05
AML adverse risk 15% 5-year survival
06
CLL early stage (Binet A) 10-year survival 80%
07
CLL advanced stage (Binet C) 5-year survival 25%
08
Pediatric ALL standard risk age 1-9: 97% 5-year DFS
09
Infant ALL very high risk: 5-year survival 50%
10
Adult ALL poor risk cytogenetics: 25% 5-year OS
11
AML NPM1 mutated without FLT3: 60% 5-year survival
12
CLL IGHV mutated low risk: 95% 5-year PFS
13
High IPSS-R MDS progressing to AML: 10% 2-year survival
14
T-ALL CNS+ at diagnosis: 5-year survival 60% with prophylaxis
15
CML low Sokal risk: 95% 8-year survival
16
ALL MRD negative day 29: 98% 5-year survival
17
AML ELN favorable: 5-year OS 66%
18
Stage I CML: 98% 5-year response rate
19
CLL TP53 mutated high risk: 2-year survival 70% with venetoclax
20
Pediatric AML high allelic ratio FLT3: 40% 5-year survival
21
Imatinib-treated CML major molecular response correlates with 95% 10-year survival
Interpretation
Survival by Risk Stage Interpretation
This array of numbers tells a triumphant story of precision warfare in hematology, where the specific enemy, its genetic armaments, and the timing of our counterattack dramatically shift the odds from near-certain victory to a desperate fight for inches.
05 · Category
Survival by Subtype20 stats
01
The 5-year survival for ALL overall is 72.5% US 2014-2020
02
AML 5-year survival rate is 31.9% all ages
03
CLL 5-year survival 88.2% per SEER 2014-2020
04
CML 5-year survival 70.6%
05
Adult ALL 5-year survival 37.2%
06
Pediatric AML 5-year survival 66.8%
07
Indolent CLL Rai stage 0: 5-year survival 98%
08
Aggressive CLL stage 4: 5-year survival 30%
09
Ph+ ALL 5-year survival 45% with TKI chemo
10
AML with t(8;21): 5-year survival 70%
11
APL subtype AML: 90% 5-year survival with ATRA+chemo
12
CML chronic phase 10-year survival 85% with imatinib
13
Hairy cell leukemia 5-year survival 97%
14
T-ALL subtype 5-year survival 75% in children
15
B-ALL adults 5-year OS 40%
16
AML secondary to MDS: 5-year survival 10%
17
CLL with 17p deletion: 5-year survival 30% pre-ibrutinib
18
CML blast crisis: 1-year survival 20%
19
UK ALL 5-year survival 70%
20
Canada AML 5-year survival 25%
Interpretation
Survival by Subtype Interpretation
These statistics are a sobering reminder that leukemia is not a single enemy, but a chaotic mosaic of battles where a patient's odds can swing from near-certain victory to a desperate fight based on a specific genetic typo and the era of medicine in which they find themselves.
06 · Category
Survival by Treatment19 stats
01
Stem cell transplant in first remission CR1 for AML high-risk: 60% 5-year survival
02
CAR-T therapy in relapsed B-ALL: 12-month survival 80%
03
Ibrutinib in relapsed CLL high-risk: 5-year OS 83%
04
Imatinib in newly diagnosed CML CP: 89% 5-year survival
05
ATRA+arsenic in APL: 97% 5-year survival
06
Blinatumomab in relapsed/refractory B-ALL adults: 43% 18-month survival
07
Venetoclax+azacitidine in elderly AML unfit: 2-year survival 39%
08
HSCT allogeneic in pediatric ALL high-risk: 80% 5-year LFS
09
Dasatinib in Ph+ ALL: 2-year survival 64%
10
Midostaurin added to chemo in FLT3+ AML: 5-year survival improved 8%
11
Rituximab maintenance in CLL post-FCR: 10-year survival 80%
12
Gemtuzumab ozogamicin in CD33+ AML: favorable risk OS 75%
13
Ponatinib in T315I CML: 1-year survival 80%
14
Inotuzumab ozogamicin in relapsed ALL: 5-year survival 27%
15
Azacitidine in high-risk MDS: median survival 24 months
16
Tisagenlecleucel CAR-T pediatric ALL: 12-month OS 96%
17
FCR chemoimmunotherapy CLL fit patients: 10-year OS 80%
18
CPX-351 in secondary AML: 1-year survival 66% vs 48%
19
Bosutinib in CML post-imatinib: 5-year survival 85%
Interpretation
Survival by Treatment Interpretation
While the odds in this leukemia battleground vary from bleak to brilliant, each statistic represents a hard-fought trench in the larger war, reminding us that modern oncology is less about finding a single cure and more about deploying an ever-growing arsenal of precision weapons against a cunning enemy.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Alexander Schmidt. (2026, February 13). Leukemia Survival Rate Statistics. Gitnux. https://gitnux.org/leukemia-survival-rate-statistics
MLA
Alexander Schmidt. "Leukemia Survival Rate Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/leukemia-survival-rate-statistics.
Chicago
Alexander Schmidt. 2026. "Leukemia Survival Rate Statistics." Gitnux. https://gitnux.org/leukemia-survival-rate-statistics.
Sources & references
22 datasets cited across this report · attribution is report-level